Joost Bakker, Author at Crossfire Oncology

About Joost Bakker

This author has not yet filled in any details.
So far Joost Bakker has created 2 blog entries.

Crossfire Oncology to present best-in-class macrocyclic BTK inhibitor CFON-026 and novel Degrader Antibody Conjugate technology at AACR 2024

The Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) annual meeting 2024. We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our

19 February 2024|

Crossfire enters state-of-the-art laboratories at the Marie Curie Building (Pivot Park)

Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs)

5 February 2024|